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Available online 21 July 2016Objective: Reports of cardiac arrhythmias and cardiac pathology at postmortem examination of patients with
epilepsy suggest a possible cardiac component of risk for sudden unexpected death in epilepsy (SUDEP). T-wave
alternans (TWA) is an established marker of cardiac electrical instability and risk for sudden death in patients
with cardiovascular disease. We determined the TWA level before vagus nerve stimulation (VNS) system
implantation and subsequently the effect of VNS on TWA in patients with drug-resistant epilepsy.
Methods: Patients (n= 28) from the Seizure Detection and Automatic MagnetMode Performance Study (E-36), a
clinical trial of the AspireSR® VNS Therapy System® (NCT01325623), were monitored with ambulatory
electrocardiograms (ECGs) ~2 weeks before de novo VNS system implantation and following 2- to 4-week VNS ti-
tration during a protocol-speciﬁed 3- to 5-day epilepsymonitoring unit staywith concurrent EEG/ECG recordings.
The TWA level was assessed interictally by the Modiﬁed Moving Average (MMA) method.
Results:At preimplantation baseline, TWAwas elevated above the 47-μV abnormality cutpoint in 23 (82%) patients
with drug-resistant epilepsy. In 16 (70%) patients, TWA level was reduced during VNS treatment to b47 μV,
thereby converting positive TWA test results to negative. Peak TWA level in all 28 patients improved (group
mean, 43%, from 72 ± 4.3 to 41 ± 2.3 μV; p b 0.0001). Vagus nerve stimulation was not associated with reduced
heart rate (77 ± 1.4 to 75 ± 1.4 beats/min; p = 0.18). Heart rate variability was unchanged.
Signiﬁcance: These ﬁndings suggest signiﬁcant interictal cardiac electrical instability in this population of patients
with drug-resistant epilepsy and suggest that VNS may be a novel approach to reducing risk.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Approximately 40% of patients with epilepsy have seizures that do
not respond adequately to antiepileptic drug therapy [1], a condition
that is an established risk factor for sudden unexpected death in epilepsy
(SUDEP). Biomarkers other than recurrent seizures for determining and
monitoring SUDEP risk are currently unavailable.ies; AspireSR, SeizureDetection
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ier).
. This is an open access article underMicrovolt T-wave alternans (TWA), a subtle, beat-to-beat ﬂuctua-
tion in the morphology and amplitude of the ST segment or T-wave in
the electrocardiogram, is a biomarker for cardiac electrical instability
that correlates with risk for sudden cardiac death (SCD) in patients
with cardiovascular disease [2]. During the postictal period in a group
of patients with focal epilepsy, Strzelczyk et al. [3] reported markedly
elevated levels of TWA. In a pilot study, we found interictal TWA levels
in excess of the 47-μV cutpoint of abnormality in 100% (9 of 9) of pa-
tients with drug-resistant epilepsy and, furthermore, that interictal
TWAwas signiﬁcantly reduced in associationwith vagus nerve stimula-
tion (VNS) [4], suggesting an effect through alterations in autonomic
tone and/or direct effects on myocardial substrate. Peak TWA level
was converted from positive to negative in 67% (4 of 6) of patients.
The objective of the present studywas to conﬁrm and further extend
these published pilot results by examining the impact of a combination
of routine intermittent (open-loop) VNS and automatic (closed-loop)
VNS on TWA in a larger subset of patients with drug-resistant epilepsythe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1.Placement of vagus nerve stimulation device. As illustrated in the insert (upper right
box), the distal end of the lead is wrapped around the nerve. The most proximal electrode
is helical and helps to anchor the lead to the vagus nerve. The ECG sensing vector is from
the generator can to the negative electrode.
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Magnet Mode Performance Study (E-36). Effects of VNS on autonomic
nervous system tone and heart rate were also assessed. Our hypotheses
were that interictal TWA would be elevated preimplantation and
reduced in association with VNS.
2. Methods
2.1. Patient selection
The Seizure Detection and Automatic Magnet Mode Performance
Study (E-36) (NCT01325623) was a prospective, multicenter study of
VNS with the AspireSR Model 106 VNS Therapy® System implantable
pulse generator (Fig. 1) in patientswith drug-resistant epilepsy and a his-
tory of ictal tachycardia (deﬁned either as 55% or a 35-beats/min increase
in heart rate to ≥100 beats/min near seizure onset) (N = 30) [5]. The
study conformed to the Declaration of Helsinki and was approved by
the Competent Authorities and Ethics Committees at the participating
centers. All patients signed informed consent. Patients were implanted
betweenApril 2011 and June 2013 at 13 European sites. To be eligible, pa-
tients also had to be at least 18 years old, be clinically diagnosed with
drug-resistant epilepsy dominated by focal seizures, have an average of
3 or more seizures per month in the 3 months prior to the screening
visit, and otherwise be in general good health and ambulatory. Patients
were excluded if they had contraindications for the existing labeling for
VNS, signiﬁcant psychiatric or addictive disorders, a history of status
epilepticus within 3 months of enrollment, were prescribed drugs
speciﬁcally for a cardiac or autonomic nervous system disorder that
potentially affected heart rate, had known clinically meaningful cardio-
vascular arrhythmias (including bradycardia), or had clinically meaning-
ful cardiovascular arrhythmias determined by a 24-hour Holter
recording obtained at the baseline visit.
Implantation techniques, postoperative care, and ramp-up and
maintenance stimulation protocols were according to standard-of-care
practices. All patients were naïve with respect to implantation of the
leads and the generator. Vagus nerve stimulation settings were as
follows: intensity, 0.75 mA and pulse width, 250 μs (medians). Pulse
frequency was 20 Hz, and duty cycle was 30 s on followed by 5 min
off. The individual settings were established by clinical personnel
without knowledge of TWA status.Medicationswere not altered during
the study period.
2.2. Ambulatory ECG recording and analysis
The patients' 24-hour electrocardiograms (ECGs) were recorded on a
single day at baseline 2 weeks prior to VNS implantation and, following
2- to 4-week VNS titration, during the ﬁnal seizure-free 24 h of the
protocol-speciﬁed 3- to 5-day hospitalization in an epilepsy monitoring
unit (EMU). The ECGs of 2 patientswere not interpretable, leaving 28 sub-
jects for our report. The baseline ECG and the ECG recorded on the ﬁnal
seizure-free day of the EMU stay were analyzed.
The TWA level was quantiﬁed with the Modiﬁed Moving Average
(MMA) method [6] in standard precordial leads V1, V5, and aVF by
an investigator (BDN) blinded to treatment status using the MARS
Ambulatory ECG Analysis System (GE Healthcare, Milwaukee, WI).
The conventional AECG conﬁgurations of V1, V5, and aVF provide satis-
factory reliability from one recording to another from the same indi-
vidual. The maximum interictal TWA level throughout the recording
is reported as the TWA value for that patient. As established in patients
with heart disease [2], a TWA cutpoint of ≥47 μV was deﬁned in this
study as an abnormal TWA test and ≥60 μV as markedly abnormal
while TWA b20 μV was taken to indicate relative cardiac electrical
stability.
Heart rate and HRV data were automatically generated by the GE
Healthcare MARS version 8.0 software for the interictal period during
theﬁrst hour of the recording. Heart rate variability (HRV)was analyzedin the frequency domain using the Fast Fourier spectral transform. Ac-
cordingly, the beat stream of the RR interval series was transformed to
compute high-frequency (HF) power within the frequency band 0.150
to 0.400 Hz and low-frequency (LF) power within the frequency band
0.040 to 0.150 Hz, reported in milliseconds squared. The LF/HF ratio
was calculated as LF frequency divided by HF frequency and
is unitless. High-frequency heart rate variability (HF HRV) is a general
indicator of parasympathetic tone, while LF HRV and the LF/HF HRV
ratio are indicators of autonomic tone and balance [7]. Normative values
of HF and LF HRV are 975 ± 203 and 1170 ± 416 ms2, respectively,
while an LF/HF HRV ratio of 1.5 to 2.0 is considered normal [7].
2.3. Statistical methods
The TWA level, HRV, and heart rate associated with VNS in AspireSR
were analyzed by Student's t-test using SAS statistical package (SAS
Institute, Cary, NC, USA). Fisher's exact test (two-tailed) was used to
assess the signiﬁcance of the change in percentage of patients with
abnormal (≤47 μV) and severely abnormal (≤60 μV) TWA comparing
levels before implant with levels at 2- to 4-weeks postimplant. Data
are reported as means ± S.E.M., with p b 0.05 considered statistically
signiﬁcant.
3. Results
3.1. Patient characteristics
Patient characteristics are as described in detail by Boon et al. [5].
Brieﬂy, all of the patients were Caucasian, and 19 (68%) were female.
Mean age at onset of epilepsy was 16 years (range: 2–43) and at study
enrollment was 40 years (range: 19–66).
3.2. Baseline interictal TWA levels
At baseline (preimplantation), interictal TWA was elevated to the
≥60-μV cutpoint of severe abnormality in 19 (68%) of the 28 patients
and ≥47-μV abnormality cutpoint in 23 patients (82%). None of the
patients had TWA b20 μV.
Table 1
Efﬁcacy measures for 28 patients enrolled in the AspireSR TWA substudy.
Variable Baseline EMU Signiﬁcance
Heart rate (beats/min) 77 ± 1.4 75 ± 1.4 0.18
T-wave alternans (μV) 72 ± 4.3 41 ± 2.3 b0.0001
TWA ≥47 μV (N, %) 23 (82%) 7 (25%) b0.0001
TWA ≥60 μV (N, %) 19 (68%) 2 (7%) b0.0001
Heart rate variability LF (ms2) 500 ± 57.0 900 ± 265.4 0.17
Heart rate variability HF (ms2) 191 ± 30.5 193 ± 29.8 0.94
Heart rate variability LF/HF ratio 3 ± 0.4 4 ± 0.4 0.12
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Vagus nerve stimulation was associated with a decrease in TWA
from baseline to the EMU stay in all 28 patients by a mean of 43%
(from 72 ± 4.3 to 41 ± 2.3 μV; p b 0.0001) (Fig. 2) (Table 1). In 16
(70%) of these 23 patients, TWA was reduced from above to below
47 μV, thereby converting positive TWA test results to negative
(Fig. 3). In 5 patients (18%), TWA remained below 47 μV, and in 7
patients (28%), TWA remained above 47 μV. In no patient did TWA
convert from negative to positive. There were no statistically signiﬁcant
correlations between VNS stimulation current intensity, duty cycle, or
the product of stimulation current intensity times duty cycle with the
reduction in TWA during the EMU stay, which is expected given that
all patients were at similar levels of output current and duty cycle.
Vagus nerve stimulation was not associated with reduced heart rates
in the group as a whole (77 ± 1.4 to 75 ± 1.4 beats/min; p = 0.18)
(Table 1).
3.4. No alteration in heart rate variability following VNS implantation
Frequency-domain HRV measures did not change from baseline
throughout the 3- to 5-day EMU stay (Table 1). However, LF HRV was
in the normal range during the EMU stay, while HF HRV remained
abnormally low and LF/HF ratio remained elevated when compared
with standards in the literature [7].
4. Discussion
4.1. Main ﬁndings
We [4] and others [3] have previously demonstrated that TWA, an
established electrocardiographic indicator of risk for life-threatening
cardiac arrhythmias in patients with heart disease as well as advanced
renal disease, is elevated between and during seizures, respectively, in
patients with drug-resistant epilepsy. We have also reported that
TWA is reduced in direct proportion to current strength of VNS in
patients with either epilepsy [4] or heart failure [8].
The present study conﬁrms and extends the results of our previous
pilot study [4]. Prior to VNS therapy, the average TWA level was 72 ±
3.9 μV. This level of TWA is comparable with that associated with high
risk for sudden death in patients with myocardial infarction, heart fail-
ure, advanced renal disease, or channelopathies including long QT [9]
and Brugada syndromes [10]; although, notably, none of the patients
in this study had a history of any of these conditions.
In this study of patients with drug-resistant epilepsy enrolled in the
AspireSR E-36 trial, automatic VNS was associated with a highly signif-
icant reduction in interictal TWA level in all 28 patients (p b 0.0001).
Nearly three-quarters (70%) of the patients with abnormal TWA levelsFig. 2. Summary data in 28 patients with interpretable EKGs in the E-36 study showing a
signiﬁcant reduction in TWA in response tomagnet-mode vagus nerve stimulation (VNS).experienced conversion from positive to negative TWA test results.
These ﬁndings are also consistent with previous results in another pa-
tient cohort [4]. It is highly germane that levels of TWA were reduced
after 3 weeks of VNS therapy by N20 μV to 41 ± 2.3 μV (p b 0.001),
since with each 20-μV increase in TWA, cardiac mortality and SCD risk
in populations without epilepsy increase by 55% and 58%, respectively
[11]. The degree of TWA reduction documented in this study, therefore,
carries the implication of reduced risk for cardiac mortality in the
studied patients.
4.2. Implications of elevated TWA in patients with epilepsy
Patients with epilepsy may exhibit cardiac effects of seizures that
can contribute to premature morbidity and SCD and/or SUDEP [12,13].
Enhanced arrhythmia susceptibility [13] and concomitant myocardial
ischemia [14] have been implicated as critical factors. Neural triggering
of ictal cardiac arrhythmias has been suggested as a factor in SUDEP
[15]. Increased ictal cardiac sympathetic nerve activity is indicated not
only by ictal surges in heart rates to N150 beats/min but also by
persistence into the postictal period [16] and by heart rate variability
analysis [17].
The hyperadrenergic state associatedwith seizures may constitute a
major component of arrhythmia risk by directly triggering rhythm dis-
turbances as well as through promoting cardiac pathology including
myocardial ﬁbrosis and degeneration in up to 33% of cases [18] and by
accelerating atherosclerosis [19], conditions that set the stage for ven-
tricular arrhythmia, perhaps especially so in association with ictal hyp-
oxemia [20]. Autopsy investigations have revealed that the hearts of
victims of SUDEP were characteristically dilated and heavier than
expected [21]. The changes have been attributed to repeated episodes
of hypoxemia [22] and/or increased catecholamine levels [18]. IncreasedFig. 3. Assessment of T-wave alternans (TWA) using the Modiﬁed Moving Average
method in a representative patient with drug-resistant epilepsy performed before and
after 4 weeks following vagus nerve stimulator (VNS) implantation, when the device
was operating at planned levels. Templates of QRS-aligned superimposed beats reveal a
separation in the morphology of the A and B beats, reﬂecting the ABABAB pattern
between the J point and T-wave, which is the alternation hallmark of TWA and its
electrophysiologic basis for estimating risk for arrhythmic death. In this patient, tracings
from before (left) and after VNS implantation (right) indicate a reduction in TWA from
67 μV, which is above the ≥47 μV cutpoint for abnormality, to 21 μV.
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been documented following uncomplicated epileptic seizures [23].
The incidence of myocardial infarction is also greater in patients with
epilepsy than in the general population [24].
Case reports of ictal ventricular ﬁbrillation in SUDEP and near-
SUDEP cases have been published [25]. However, Stecker and Chugh
concluded from their analysis of the Oregon Sudden Unexpected
Death Study that SUDEP did not typically occur in association with
seizures [26]. Nevertheless, a diagnosis of epilepsy increases risk for
SCD by 3-fold (adjusted OR: 2.9 [95% CI: 1.1–8.0]; p = 0.034) over the
general population, as reported in the community-based Amsterdam
Resuscitation Studies (ARREST) [27]. These investigators concluded
that cardiovascular disease rather than epilepsy characteristics is the
main determinant of VT/VF in people with epilepsy and that SCD and
SUDEP are partially overlapping disease entities [28]. Thus, these obser-
vations suggest that SUDEP associated with cardiac arrhythmia could
potentially, in some instances, be triggered by factors other than
seizures in vulnerable patients.
4.3. Potential mechanisms for cardiac protection
Explaining the precisemechanismswhereby VNS could reduce TWA
in patients with drug-resistant epilepsy is particularly challenging in
light of the multifactorial effects of chronic VNS. Two general pathways
are likely to be involved. Speciﬁcally, it is likely that inﬂuences on the
central nervous system can contribute to reduction in risk for arrhyth-
mia, potentially by suppression of seizure activity. However, whether
reduction in TWA by VNS correlates with decreased incidence of
seizures remains to be established, and there are mixed reports of the
capacity of VNS to reduce SUDEP of any cause [29,30]. Second, VNS is
known to exert pleiotropic protective effects via peripheral inﬂuences.
These include reduction in inﬂammation, cytokine expression, apopto-
sis, heart rate, and sympathetic nerve effects [31–35]. Because the latter
two inﬂuences have been shown to affect TWA magnitude directly [2],
they are strong putative mechanisms that require further investigation.
Excessive sympathetic nerve activity independent of heart rate can
increase TWA, and its antagonism can reduce TWA. Vagus nerve
stimulation is antisympathetic through classic mechanisms involving
accentuated antagonism [36] and inhibition of stellate ganglion activity
[32]. It is relevant that left-sided VNS is effective in reducing TWA, as
Shen et al. [37] have shown that stimulation of the left vagus nerve re-
sults in ipsilateral inhibition of the left stellate ganglion. This structure
exerts a major inﬂuence on susceptibility to VF, as evidenced by the ef-
fectiveness of left stellectomy in reducing SCD [38]. The recent ﬁndings
that TWA is reduced in association with VNS therapy and that HRT
slope, a measure of baroreceptor sensitivity [39], is improved in the
ANTHEM-HF study of patients with heart failure [8] also implicate
effects on autonomic reﬂexes in VNS-mediated reduction in TWA.
While heart rate has been implicated as a factor in TWA level, it is not
likely to have played a major role in the present study as heart rate
was not reduced in the group as a whole.
In the future, it will be important to determine the persistence of the
reduction in TWA in patients treated with VNS and beyond the setting
of the telemetry unit. However, it is encouraging that, after one year of
VNS in ANTHEM-HF, TWA remained reduced [8].
4.4. Conclusions and implications
The ﬁndings support our hypotheses and conﬁrm previous pilot
data, showing that interictal TWA is elevated preimplantation and re-
duced in association with VNS in patients with drug-resistant epilepsy.
The magnitude of the effect on TWA is highly signiﬁcant, with all
patients showing a reduction and with a 70% conversion rate from pos-
itive to negative test results. We further extended our previous pilot
data by showing in this study that signiﬁcant reductions in TWA can
occur after only three weeks of VNS. Taken together, these observationsimplicate a cardiac basis for SUDEP that can be assessed with TWA,
which should be further studied as both a biomarker and a therapeutic
target and the potential for reduced risk for cardiac-mediated SUDEP
with VNS.
Funding
This study was funded by a grant VERR004 from LivaNova, Inc. to
Beth Israel Deaconess Medical Center (BIDMC), RL Verrier, P.I.
Ethical publication statement
We conﬁrm that we have read the Journal's position on issues in-
volved in ethical publication and afﬁrm that this report is consistent
with those guidelines.
Disclosure of conﬂicts of interest
Drs. Verrier and Nearing receive royalty fromGeorgetown University
and BIDMC for the Modiﬁed Moving Average method for TWA analysis,
which is licensed by GE Healthcare. Dr. Olin is employed by LivaNova,
PLC. Drs. Boon and Schachter declare no conﬂicts of interest.
References
[1] Ryvlin P, Gilliam FG, Nguyen DK, Colicchio G, Iudice A, Tinuper P, et al. Long-term ef-
fect of vagus nerve stimulation on quality of life in patients with pharmacoresistant
focal epilepsy: the PuLsE (open prospective randomized long-term effectiveness)
trial. Epilepsia 2014;55:893–900.
[2] Verrier RL, Klingenheben T, Malik M, El-Sherif N, Exner D, Hohnloser S, et al.
Microvolt T-wave alternans: physiologic basis, methods of measurement, and
clinical utility. Consensus guideline by the International Society for Holter and
Noninvasive Electrocardiology. J Am Coll Cardiol 2011;44:1309–24.
[3] Strzelczyk A, Adjei P, Scott CA, Bauer S, Rosenow F, Walker MC, et al. Postictal
increase in T-wave alternans after generalized tonic–clonic seizures. Epilepsia
2011;52:2112–7.
[4] Schomer AC, Nearing BD, Schachter SC, Verrier RL. Vagus nerve stimulation reduces
cardiac electrical instability assessed by quantitative T-wave alternans analysis in
patients with drug-resistant focal epilepsy. Epilepsia 2014;55:1996–2002.
[5] Boon P, Vonck K, van Rijckevorsel K, El Tahry R, Elger CE,Mullatti N, et al. A prospective,
multicenter study of cardiac-based seizure detection to activate vagus nerve stimula-
tion. Seizure 2015;32:52–61.
[6] Nearing BD, Verrier RL. Modiﬁedmoving averagemethod for T-wave alternans anal-
ysis with high accuracy to predict ventricular ﬁbrillation. J Appl Physiol 2002;92:
541–9.
[7] Heart rate variability: standards of measurement, physiological interpretation
and clinical use. Task Force of the European Society of Cardiology and the North
American Society of Pacing and Electrophysiology. Circulation 1996;93:1043–65.
[8] Libbus I, Nearing BD, Amurthur B, KenKnight BH, Verrier RL. Autonomic regulation
therapy suppresses quantitative T-wave alternans and improves baroreﬂex sensitivity
in heart failure patients enrolled in the ANTHEM-HF study. Heart Rhythm 2016;13:
721–8.
[9] Takasugi N, Goto H, Takasugi M, Verrier RL, Kuwahara T, Kubota T, et al. Prevalence
of microvolt T-wave alternans in patients with long QT syndrome and its association
with torsade de pointes. Circ Arrhythm Electrophysiol 2016;9, e003206. http://dx.
doi.org/10.1161/CIRCEP.115.003206.
[10] Verrier RL, Ikeda T. Ambulatory ECG-based T-wave alternans monitoring for risk as-
sessment and guiding medical therapy: mechanisms and clinical applications. Prog
Cardiovasc Dis 2013;56:172–85.
[11] Leino J, Verrier RL, Minkkinen M, Lehtimäki T, Viik J, Lehtinen R, et al. Importance of
regional speciﬁcity of T-wave alternans in assessing risk for cardiovascular mortality
and sudden cardiac death during routine exercise testing. Heart Rhythm 2011;8:
385–90.
[12] Ryvlin P, Montavont A, Kahane P. Sudden unexpected death in epilepsy: from
mechanisms to prevention. Curr Opin Neurol 2006;19:194–9.
[13] Verrier RL, Schachter SC. Neurocardiac interactions in sudden unexpected death in
epilepsy: can ambulatory electrocardiogram-based assessment of autonomic
function and T-wave alternans help to evaluate risk? In: Lathers CM, Schraeder
PL, BungoMW, Leestma JE, Wannamaker BB, Verrier RL, editors. Sudden unexpected
death in epilepsy: mechanisms and newmethods for analyzing risks. Boca Raton FL:
Taylor and Francis; 2015. p. 125–38.
[14] Tigaran S, Molgaard H, McClelland R, Dam M, Jaffe AS. Evidence of cardiac ischemia
during seizures in drug refractory epilepsy patients. Neurology 2003;60:492–5.
[15] Devinsky O. Effects of seizures on autonomic and cardiovascular function. Epilepsy
Curr 2004;4:43–6.
[16] Surges R, Adjei P, Kallis C, Erhuero J, Scott CA, Bell GS, et al. Pathologic cardiac repo-
larization in pharmacoresistant epilepsy and its potential role in sudden unexpected
death in epilepsy: a case–control study. Epilepsia 2010;51:233–42.
89R.L. Verrier et al. / Epilepsy & Behavior 62 (2016) 85–89[17] Ronkainen E, Korpelainen JT, Heikkinen E, Myllylä VV, Huikuri HV, Isojärvi JI. Cardiac
autonomic control in patients with refractory epilepsy before and during vagus
nerve stimulation treatment: a one-year follow-up study. Epilepsia 2006;47:
556–62.
[18] Natelson BH, Suarez RV, Terrence CF, Turizo R. Patients with epilepsy who die
suddenly have cardiac disease. Arch Neurol 1998;55:857–60.
[19] Hamed SA. Atherosclerosis in epilepsy: its causes and implications. Epilepsy Behav
2014;41:290–6.
[20] Seyal M, Pascual F, Lee CY, Li CS, Bateman LM. Seizure-related cardiac repolarization
abnormalities are associated with ictal hypoxemia. Epilepsia 2011;52:2105–11.
[21] Leestma JE, Walczak T, Hughes JR, Kalelkar MB, Teas SS. A prospective study on sud-
den unexpected death in epilepsy. Ann Neurol 1989;26:195–203.
[22] Moseley B, Bateman L, Millichap JJ, Wirrell E, Panayiotopoulos CP. Autonomic epilep-
tic seizures, autonomic effects of seizures, and SUDEP. Epilepsy Behav 2013;26:
375–85.
[23] Hajsadeghi S, Afsharian S, Fereshtehnejad SM, Keramati MR, Mollahoseini R. Serum
levels of cardiac troponin I in patients with uncomplicated epileptic seizure. Arch
Med Res 2009;40:24–8.
[24] Janszky I, Hallqvist J, Tomson T, Ahlbom A, Mukamal KJ, Ahnve S. Increased risk and
worse prognosis of myocardial infarction in patients with prior hospitalization for
epilepsy—the Stockholm Heart Epidemiology Program. Brain 2009;132(Pt 10):
2798–804.
[25] Lathers CM, Schraeder PL, Schachter SC, Verrier RL, Wannamaker BB. Clinical cases
classiﬁed as SUDEP cluster risk factor identiﬁers. In: Lathers CM, Schraeder PL,
Bungo MW, Leestma JE, Wannamaker BB, Verrier RL, editors. Sudden unexpected
death in epilepsy: mechanisms and new methods for analyzing risks. Boca Raton
FL: Taylor and Francis; 2015. p. 65–86.
[26] Stecker EC, Reinier K, Uy-Evanado A, Teodorescu C, Chugh H, Gunson K, et al.
Relationship between seizure episode and sudden cardiac arrest in patients with
epilepsy: a community-based study. CIRCEP 2013;6:912–6.
[27] Bardai A, Lamberts RJ, Blom MT, Spanjaart AM, Berdowski J, van der Staal SR, et al.
Epilepsy is a risk factor for sudden cardiac arrest in the general population. PLoS
One 2012;7, e42749.[28] Lamberts RJ, Blom MT, Wassenaar M, Bardai A, Leijten FS, de Haan GJ, et al. Sudden
cardiac arrest in people with epilepsy in the community: circumstances and risk
factors. Neurology 2015;85:212–8.
[29] Annegers JF, Coan SP, HauserWA, Leestma J. Epilepsy, vagal nerve stimulation by the
NCP system, all-cause mortality, and sudden, unexpected, unexplained death.
Epilepsia 2000;41:549–53.
[30] Granbichler CA, Nashef L, Selway R, Polkey CE. Mortality and SUDEP in epilepsy
patients treated with vagus nerve stimulation. Epilepsia 2015;56:291–6.
[31] Schwartz PJ, De Ferrari GM. Vagal stimulation for heart failure: background and ﬁrst
in-man study. Heart Rhythm 2009;6:S76–81.
[32] De Ferrari GM, Crijns HJGM, Borggrefe M, Milasinovic G, Smid J, Zabel M. Chronic
vagus nerve stimulation: a new and promising therapeutic approach for chronic
heart failure. Eur Heart J 2011;32:847–55.
[33] Li W, Olshansky B. Inﬂammatory cytokines and nitric oxide in heart failure and
potential modulation by vagus nerve stimulation. Heart Fail Rev 2011;16:137–45.
[34] Sabbah HN, Ilsar I, Zaretsky A, Rastogi S,WangM, Gupta RC. Vagus nerve stimulation
in experimental heart failure. Heart Fail Rev 2011;16:171–8.
[35] Shen MK, Zipes DP. Role of the autonomic nervous system in modulating cardiac
arrhythmias. Circ Res 2014;114:1004–21.
[36] Kolman BS, Verrier RL, Lown B. The effect of vagus nerve stimulation upon vulnera-
bility of the canine ventricle: role of sympathetic–parasympathetic interactions.
Circulation 1975;52:578–85.
[37] Shen MJ, Shinohara T, Park HW, Frick K, Ice DS, Choi EK, et al. Continuous low-level
vagus nerve stimulation reduces stellate ganglion nerve activity and paroxysmal
atrial tachyarrhythmias in ambulatory canines. Circulation 2011;123:2204–12.
[38] Schwartz PJ, Motolese M, Pollavini G, Lotto A, Ruberti U, Trazzi R, et al, for the Italian
Sudden Death Prevention Group. J Cardiovasc Electrophysiol 1992;3:2–16.
[39] Bauer A, Malik M, Schmidt G, Barthel P, Bonnemeier H, Cygankiewicz I, et al. Heart
rate turbulence: standards of measurement, physiological interpretation, and clini-
cal use. J Am Coll Cardiol 2008;52:1353–65.
